Related Experiment Video
Updated: Aug 11, 2025
10:28
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.2K
Recent Progress in Immunotherapy for Gastric Cancer
Jeesun Yoon1, Tae-Yong Kim1,2, Do-Youn Oh1,2,3
1Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Journal of Gastric Cancer
|February 8, 2023
Summary
Immunotherapy, including anti-PD-1 antibodies like nivolumab and pembrolizumab, has significantly improved survival for advanced gastric cancer (GC). Research is expanding immunotherapy to early GC and exploring new treatment combinations.
Area of Science:
- Oncology
- Immunology
Background:
- Gastric cancer (GC) is a leading cause of cancer mortality globally.
- Advanced GC (AGC) traditionally has a poor prognosis with limited survival.
- Immunotherapy has emerged as a pivotal treatment strategy in advanced cancers.
Purpose of the Study:
- To review recent advancements in immunotherapy for gastric cancer.
- To discuss the role of immune checkpoint inhibitors (ICIs) in GC treatment.
- To explore potential immunotherapy biomarkers and future applications in GC.
Main Methods:
- Review of Phase III clinical trials (ATTRACTION-2, CheckMate-649).
- Analysis of immunotherapy efficacy in third-line and first-line settings for AGC.
- Examination of combination therapies involving anti-PD-1 antibodies, chemotherapy, and targeted agents.
Main Results:
- Nivolumab (anti-PD-1) improved overall survival (OS) in third- or later-line AGC.
- Nivolumab plus chemotherapy improved OS in first-line, HER2-negative AGC.
- Pembrolizumab plus chemotherapy and trastuzumab improved response rates in HER2-positive AGC.
Conclusions:
- Immune checkpoint inhibitors (ICIs) are integral to current advanced GC treatment.
- Ongoing trials investigate ICI rechallenge and novel combinations.
- Immunotherapy is being explored for perioperative and postoperative settings in early GC.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
616
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
616
01:30Cancer Vaccines
473
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
473
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K